Solomon Moshkevich Sells 23,205 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 23,205 shares of Natera stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the completion of the sale, the insider owned 144,992 shares of the company’s stock, valued at $34,035,422.08. This trade represents a 13.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $68,855.00.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.

Natera Stock Down 0.5%

Shares of NTRA opened at $241.58 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm’s 50 day moving average price is $234.18 and its 200 day moving average price is $191.17. The company has a market cap of $33.42 billion, a P/E ratio of -105.49 and a beta of 1.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter last year, the firm earned ($0.26) EPS. The business’s revenue was up 34.7% on a year-over-year basis. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rakuten Investment Management Inc. purchased a new stake in shares of Natera during the 3rd quarter worth approximately $34,096,000. SWS Partners raised its stake in Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after acquiring an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after acquiring an additional 5,614 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after acquiring an additional 19,576 shares in the last quarter. Finally, Orion Porfolio Solutions LLC grew its holdings in shares of Natera by 68.8% during the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 4,946 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. BTIG Research upped their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Wells Fargo & Company lifted their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Finally, Barclays increased their price objective on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.